- Home
- PBYI
as 01-17-2025 4:00pm EST
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 153.2M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 821.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | 492.79 |
| 52 Week Low/High: | $2.23 - $7.73 | Next Earning Date: | 02-27-2025 |
| Revenue: | $243,569,000 | Revenue Growth: | 6.30% |
| Revenue Growth (this year): | -3.07% | Revenue Growth (next year): | -7.16% |
Stock Insider Trading Activity of Puma Biotechnology Inc (PBYI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| NOUGUES MAXIMO F | PBYI | Chief Financial Officer | Jan 2 '25 | Sell | $3.15 | 10,227 | $32,232.44 | 152,295 | |
| HUNT DOUGLAS M | PBYI | See Remarks | Jan 2 '25 | Sell | $3.15 | 8,633 | $27,208.63 | 124,594 | |
| AUERBACH ALAN H | PBYI | President and CEO | Jan 2 '25 | Sell | $3.15 | 33,841 | $106,656.68 | 7,029,674 | |
| Ludwig Jeffrey Jerome | PBYI | Chief Commercial Officer | Jan 2 '25 | Sell | $3.15 | 9,437 | $29,742.59 | 108,951 |
Latest Puma Biotechnology Inc News
PBYI Breaking Stock News: Dive into PBYI Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Is Now The Time To Put Puma Biotechnology (NASDAQ:PBYI) On Your Watchlist?
Zacks
13 days ago
Best Value Stocks to Buy for January 6th
Business Wire
15 days ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zacks
17 days ago
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
Simply Wall St.
22 days ago
US Penny Stocks With Promise: 3 Picks Under $200M Market Cap
Zacks
22 days ago
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why
Zacks
23 days ago
Is Bristol Myers Squibb (BMY) Stock Undervalued Right Now?
Zacks
25 days ago
Best Momentum Stocks to Buy for December 24th
Compare PBYI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PBYI Puma Biotechnology Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.